UBS Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18.4M | Sell |
303,300
-577,100
| -66% | -$33.6M | ﹤0.01% | 2685 |
|
|
2025
Q4 | $47.5M | Buy |
880,400
+637,595
| +263% | +$30.7M | 0.01% | 1679 |
|
|
2025
Q3 | $11M | Buy |
242,805
+61,250
| +34% | +$2.86M | ﹤0.01% | 3192 |
|
|
2025
Q2 | $8.4M | Sell |
181,555
-355,172
| -66% | -$17.4M | ﹤0.01% | 3269 |
|
|
2025
Q1 | $32.7M | Sell |
536,727
-126,800
| -19% | -$7.39M | 0.01% | 1878 |
|
|
2024
Q4 | $37.5M | Buy |
663,527
+6,180
| +0.9% | +$345K | 0.01% | 1711 |
|
|
2024
Q3 | $34M | Buy |
657,347
+510,920
| +349% | +$24M | 0.01% | 1420 |
|
|
2024
Q2 | $6.08M | Sell |
146,427
-155,000
| -51% | -$6.94M | ﹤0.01% | 2664 |
|
|
2024
Q1 | $16.3M | Sell |
301,427
-1,471,673
| -83% | -$75M | ﹤0.01% | 1857 |
|
|
2023
Q4 | $91M | Buy |
1,773,100
+175,200
| +11% | +$9.2M | 0.03% | 622 |
|
|
2023
Q3 | $92.7M | Buy |
1,597,900
+556,500
| +53% | +$34.1M | 0.03% | 530 |
|
|
2023
Q2 | $66.6M | Sell |
1,041,400
-212,300
| -17% | -$14.2M | 0.02% | 675 |
|
|
2023
Q1 | $86.9M | Sell |
1,253,700
-15,300
| -1% | -$1.08M | 0.03% | 509 |
|
|
2022
Q4 | $91.3M | Buy |
1,269,000
+721,500
| +132% | +$54.4M | 0.03% | 523 |
|
|
2022
Q3 | $38.9M | Buy |
547,500
+54,200
| +11% | +$3.93M | 0.02% | 830 |
|
|
2022
Q2 | $38M | Buy |
493,300
+80,000
| +19% | +$6.09M | 0.02% | 897 |
|
|
2022
Q1 | $30.2M | Buy |
413,300
+148,300
| +56% | +$9.96M | 0.01% | 1149 |
|
|
2021
Q4 | $16.5M | Buy |
265,000
+211,834
| +398% | +$12.4M | ﹤0.01% | 1714 |
|
|
2021
Q3 | $3.15M | Hold |
53,166
| – | – | ﹤0.01% | 3162 |
|
|
2021
Q2 | $3.55M | Sell |
53,166
-1,022,600
| -95% | -$66.7M | ﹤0.01% | 3031 |
|
|
2021
Q1 | $67.9M | Buy |
1,075,766
+550,966
| +105% | +$34.3M | 0.02% | 674 |
|
|
2020
Q4 | $32.6M | Buy |
524,800
+100,900
| +24% | +$6.2M | 0.01% | 1033 |
|
|
2020
Q3 | $25.6M | Sell |
423,900
-103,800
| -20% | -$6.25M | 0.01% | 1016 |
|
|
2020
Q2 | $31M | Sell |
527,700
-347,000
| -40% | -$20.8M | 0.01% | 822 |
|
|
2020
Q1 | $48.8M | Buy |
874,700
+292,200
| +50% | +$17.9M | 0.02% | 552 |
|
|
2019
Q4 | $37.4M | Buy |
582,500
+89,100
| +18% | +$5.1M | 0.01% | 947 |
|
|
2019
Q3 | $25M | Sell |
493,400
-63,700
| -11% | -$2.99M | 0.01% | 1092 |
|
|
2019
Q2 | $25.3M | Sell |
557,100
-77,900
| -12% | -$3.63M | 0.01% | 1048 |
|
|
2019
Q1 | $30.3M | Sell |
635,000
-147,300
| -19% | -$7.34M | 0.01% | 897 |
|
|
2018
Q4 | $40.7M | Buy |
782,300
+744,200
| +1,953% | +$40M | 0.02% | 685 |
|
|
2018
Q3 | $2.37M | Buy |
38,100
+1,600
| +4% | +$95K | ﹤0.01% | 3072 |
|
|
2018
Q2 | $2.02M | Sell |
36,500
-1,521,800
| -98% | -$82.2M | ﹤0.01% | 3158 |
|
|
2018
Q1 | $98.6M | Buy |
1,558,300
+1,335,400
| +599% | +$85.9M | 0.04% | 392 |
|
|
2017
Q4 | $13.7M | Sell |
222,900
-20,500
| -8% | -$1.28M | 0.01% | 1482 |
|
|
2017
Q3 | $15.5M | Buy |
243,400
+241,630
| +13,651% | +$14.1M | 0.01% | 1287 |
|
|
2017
Q2 | $99K | Sell |
1,770
-4,013,080
| -100% | -$218M | ﹤0.01% | 5168 |
|
|
2017
Q1 | $218M | Buy |
4,014,850
+2,960,976
| +281% | +$162M | 0.12% | 197 |
|
|
2016
Q4 | $61.6M | Buy |
1,053,874
+915,074
| +659% | +$50M | 0.03% | 457 |
|
|
2016
Q3 | $7.48M | Buy |
138,800
+78,800
| +131% | +$5.06M | ﹤0.01% | 1654 |
|
|
2016
Q2 | $4.41M | Buy |
+60,000
| New | +$4.24M | ﹤0.01% | 2052 |
|
|
2016
Q1 | – | Sell |
-36,700
| Closed | -$2.52M | – | 7650 |
|
|
2015
Q4 | $2.52M | Sell |
36,700
-8,819
| -19% | -$583K | ﹤0.01% | 2590 |
|
|
2015
Q3 | $2.69M | Sell |
45,519
-19,281
| -30% | -$1.22M | ﹤0.01% | 2480 |
|
|
2015
Q2 | $4.31M | Buy |
64,800
+34,000
| +110% | +$2.24M | ﹤0.01% | 2223 |
|
|
2015
Q1 | $1.99M | Sell |
30,800
-196,300
| -86% | -$12.3M | ﹤0.01% | 2931 |
|
|
2014
Q4 | $13.4M | Buy |
+227,100
| New | +$12.8M | 0.01% | 1275 |
|
Other funds holding BMY
VCM
VPM
UBS Group's BMY Position: Q1 2026 in Review
UBS Group increased its Bristol-Myers Squibb (BMY) stake by 17% in Q1 2026, buying an estimated $61.2M and bringing the position to 7,200,449 shares worth $437M. The position accounts for 0.07% of the portfolio, ranked #301.
UBS Group first reported a position in BMY in Q4 2014 and has held it in 46 quarters since. The position peaked at $652M in Q4 2019. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- UBS Group held 7,200,449 shares of Bristol-Myers Squibb worth $437M as of Q1 2026.
- UBS Group bought 1,049,337 Bristol-Myers Squibb shares in Q1 2026, an estimated $61.2M.
- Bristol-Myers Squibb made up 0.07% of UBS Group's portfolio in Q1 2026, its #301 holding.
- UBS Group first reported a position in Bristol-Myers Squibb in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Bristol-Myers Squibb position peaked at $652M in Q4 2019.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.